bioRxiv Science⌕ Search

Biology subjects

Zirngibl, M.

Publications and source records attributed to Zirngibl, M..

2 recordsLinked to original sources

Fibroblast-derived Collagen VI shapes the structure and function of the tumor-immune microenvironment in clear cell renal cell carcinoma

The importance of the extracellular matrix (ECM) influencing tumor biology in stroma-rich tumors is well established. However, the relevance of individual ECM proteins in rather stroma-poor cancers such as clear cell renal cell carcinoma (ccRCC) is ill-defined. Using bulk proteomics, spatial imaging, and single-cell transcriptomics, we identify collagen VI (COL6) as a predominant ECM component of the ccRCC interstitial stroma, synthesized primarily by fibroblasts and pericytes. Using cell-derived matrix (CDM) models, we demonstrate that COL6 is essential for maintaining an isotropic ECM network architecture and governs the broader matrisomal composition, with direct pro-proliferative consequences for tumor cells both in vitro and in situ. Granular spatial analysis reveals that COL6-rich stromal septa constrain tumor-infiltrating T cells to boundary zones, where CD8+PD1+ phenotypes predominate. Importantly, tyrosine kinase inhibition (TKI) with cabozantinib suppresses COL6 expression in fibroblasts in vitro and in ex vivo tumor models, mirroring COL6-depleted CDM phenotypes. Our findings establish COL6 as a central stromal regulator of ccRCC tumor biology and immune contexture, revealing ECM remodeling as an underappreciated mechanism of TKI action, with implications for combination immunotherapy strategies.

cancer biology↗

Proteomic characterization of sporadic clear cell renal cell carcinoma reveals a matrix-dense pseudocapsule and heterogeneous tumor subtypes

Clear cell renal cell carcinoma (ccRCC) frequently develops a fibrotic pseudocapsule (PC) at the tumor boundary, yet its implications in the disease remain incompletely defined. We performed DIA-based proteomics on formalin-fixed, paraffin-embedded (FFPE) specimens of sporadic ccRCC from 153 patients, comprising 142 tumor, 123 pseudocapsule (PC), and 121 non-malignant adjacent tissue (NAT) samples. The PC displayed a distinctive proteomic signature characterized by matrix accumulation, enhanced remodeling and ECM-cell signaling, consistent with a signaling-competent boundary and active growth factor sequestration rather than a passive fibrotic barrier. Within the tumor, we observed canonical metabolic reprogramming with upregulated glycolysis and hypoxia markers and suppression of aerobic metabolism, accompanied by strong cell-cycle and pro-angiogenic signatures. Immune programs included increased antigen processing and presentation, together with elevated inflammasome and pyroptosis signatures. T-cell markers were enriched in the PC, indicating an immune-active boundary. Among tumors, we identified five distinct proteomic subtypes (C1-C5) spanning proliferative/mitotic, metabolic, immune/EMT/mTOR, and ECM phenotypes. Semi-specific peptide analysis indicated elevated endogenous proteolysis in the tumor and varied across clusters, with C1 and C5 showing the greatest proteolytic burden. Mechanotransduction features showed only modest PC elevation but were dominated by inter-patient variation. The present study defines a matrix-rich, signaling-active pseudocapsule and a classification of heterogeneous tumor subtypes in sporadic ccRCC. The framework provides a compartment-resolved, cluster-informed approach, and it highlights actionable axes of potential clinical relevance.

molecular biology↗